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Delayed treatment with enalapril halts tubulointerstitial fibrosis
in rats with obstructive nephropathy
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Renal Division, Department of Medicine and the Department of Cell Biology and Physiology, Washington University School of Medicine and The Jewish
Hospital of St. Louis, St. Louis, Missouri, USA
Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats
with obstructive nephropathy. Tubulointerstitial fibrosis in unilateral
ureteral obstruction (UUO) is driven by increased levels of angiotensin II
(Ang II). In this study, we examined the time course of the fibrotic process
in rats with UUO and explored the effect of delayed administration of an
angiotensin converting enzyme (ACE) inhibitor, enalapril, on the tubulo-
interstitial fibrosis of obstructive uropathy. Rats were sacrificed at 3, 5, 8,
or 10 days after UUO was initiated. Some rats did not receive treatment,
whereas others were treated with enalapril from day 4 to day 8 or from day
6 to day 10 after the Onset of UUO. The levels of mRNA for transforming
growth factor I3 (TGF-/31), collagen type IV (collagen IV), and tissue
inhibitor of metalloproteinase (TIMP-1) were measured at each time
point by reverse transcription-polymerase chain reaction (RT-PCR). The
relative volume of the tubulointerstitium (Vv) was measured by a point-
counting method. Monocyte/macrophage infiltration and collagen IV
protein deposition were examined histologically using specific antibodies.
There were significant increases in TGF-f31, TIMP-1, and collagen IV
mRNAs in the obstructed kidney. Treatment with enalapril on day 4
through day 8 or on day 6 through day 10 significantly reduced the
elevated mRNA levels of these compounds in the obstructed kidney.
Histological studies showed augmented Vv, monocyte/macrophage infil-
tration, interstitial cr-smooth muscle actin expression, and collagen IV
protein deposition on days 3, 5, 8, or 10 of UUO; enalapril treatment from
day 4 to 8 or from day 6 to 10 halted and to an extent reversed these
increases. These data suggest that enalapril administration after several
days of UUO is an effective means of preventing the progression of
tubulointerstitial fibrosis of obstructive uropathy.
Tubulointerstitial fibrosis is the major histopathological change
in several models of experimental renal disease [1—6]. Unilateral
ureteral obstruction (UUO) is a model of experimental renal
injury characterized by progressive tubulointerstitial fibrosis
[5—10]. Acute or chronic ureteral obstruction occurs in a variety of
clinical settings (congenital hydronephrosis, tumor, calculus, be-
nign prostatic hypertrophy, trauma, pregnancy, etc.) [11]. Individ-
uals with chronic obstructive uropathy may progress to end-stage
renal disease [12]. Although relief of the obstruction is the
therapeutic option of choice [11], this may not always be feasible
and other therapeutic modalities need to be developed to reverse
or halt the eventual progression of the renal disease that occurs as
a consequence of obstructive uropathy.
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We found that increased levels of transforming growth factor f3
(TGF-/31) in kidney tubules have an important role in the
initiation of tubulointerstitial fibrosis in rats with UUO [13] and
that this upregulation of TGF-/31 is accompanied by an increased
expression of collagen type IV (collagen IV) mRNA and subse-
quent deposition of collagen [6]. Since these alterations are
prevented to a large extent by the prior or concomitant adminis-
tration of an angiotensin converting enzyme (ACE) inhibitor or a
specific angiotensin II (Ang II) receptor antagonist [6, 14], it is clear
that Ang II has a critical role in the overall process of tubulointer-
stitial fibrosis through an increase in TGF-J31. However, it is not
known if interrupting Ang II generation after the onset of obstructive
uropathy will alter the progression of tubulointerstitial fibrosis.
The mechanisms of progression of tubulointerstitial fibrosis
have not been completely elucidated. TGF-pl modulates the
synthesis of extracellular matrix components including collagen
IV by increasing matrix protein mRNA levels, inhibits the pro-
duction of metalloproteinases and also increases the production
of metalloproteinase inhibitors [15]. All these factors and the
proliferation of interstitial fibroblasts and infiltration of the renal
parenchyma by monocytes/macrophages promote the develop-
ment of tubulointerstitial fibrosis. The purpose of this study was to
examine the temporal relationship of factors underlying the
development of tubulointerstitial fibrosis in rats with UUO and to
explore the potential effect of the ACE inhibitor enalapril admin-
istered after tubulointerstitial fibrosis is already present.
Methods
Animals and experimental protocol
Female Sprague-Dawley rats (Harlan Bioproducts, Indianapo-
lis, IN, USA) weighing 180 to 228 g were used in these experi-
ments. Most of the rats underwent unilateral ureteral obstruction
(UUO) as described previously [6, 13]. Under halothane anesthe-
sia the left ureter was ligated with 4-0 silk at two points and cut
between the ligatures. Control rats (N = 5), also referred to as
normal rats, underwent no surgical manipulation while 3 rats
underwent sham operations in which the left ureter was manipu-
lated but not ligated. All animals were fed a standard rat chow and
given tap water ad libitum; rats with UUO were sacrificed under
pentobarbital anesthesia (5.0 mg/kg body wt) given intraperitone-
ally after three days (N = 7), five days (N = 8), eight days (N =
8) or 10 days (N = 5) of UUO. Eight animals were administered
the ACE inhibitor enalapril in the drinking water (200 mg/liter)
subsequent to obstruction, from day 4 to day 8, and then sacrificed
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on day 8, while 5 rats were treated with the ACE inhibitor from
day 6 to day 10 and then sacrificed on day 10.
Tissue preparation and RNA extraction
For histological studies three to five animals from each group
(as defined by the duration of the UUO) were anesthetized with
pentobarhital. Their kidneys were perfused in vivo with cold
Hank's balanced salt solution (HBSS), pH 7.2, and then with a
tissue fixative (Histochoice, Amresco, Solon, OH, USA) for 10
minutes. The kidneys were removed, sliced axially in 3-mm thick
sections, immersed in the same fixative for four hours at 4°C,
washed with HBSS and embedded in paraffin. Paraffin sections, 4
jiM in thickness, were subjected to Azan-Mallory staining or
immunochemical analysis.
For RNA extraction, kidneys of the rest of the animals in each
group were perfused in situ with cold HBSS. In some of these
animals an axial slice, 2 mm thick, was immersed in Histochoice
for histological evaluation. We have observed no obvious differ-
ences between samples fixed in Histochoice and those fixed in situ.
The remaining renal cortex was dissected immediately and minced
in cold RNAzol (Cinna/Bioteck, Houston, TX, USA). Total RNA
was extracted using the guanidinium isothiocyanatc (RNAzo1)
method [161. The total RNA was dissolved in RNAse-free water
(Sigma, St. Louis, MO, USA) and quantitated precisely by UV
speetrophotometry at 260 nm and 280 nm. RNA with an 0D2601280
ratio greater than 1.9 was used for eDNA synthesis.
Immunohistochemical studies and morphometric analysis
The deparaffinized sections were washed in phosphate buffered
saline (PBS) for 10 minutes each of three times, preincubated in
blocking solution (10% goat or rabbit serum in PBS) for 30
minutes, washed in PBS three times and then incubated with
primary antibody in PBS for two hours at room temperature.
Mouse monoclonal antibody against monocytes/macrophages,
ED-i (1:2000 dilution, Harlan Bioproducts, Indianapolis, IN,
USA), n-smooth muscle actin (HHF35 from Biogenex, San
Ramon, CA, USA), and goat polyclonal antibody against type IV
collagen (collagen IV) (1:40 dilution, Southern Biotechnology
Associates, Inc., Birmingham, AL, USA) were used as primary
antibodies. Each section was washed three times in PBS and
incubated with a second antibody in PBS for 30 minutes. Alkaline
phosphatase conjugated goat anti-mouse lgG or rabbit anti-goat
lgG (Sigma) was used as a second antibody, both at 1:1000
dilutions. After washing with PBS three times, the section was
developed with Fast Rcd/Naphthol.
Monocyte/macrophage infiltration was determined by the num-
ber of cells within the cortex that stained positively with the ED-i
antibody. Twenty randomly chosen nonoverlapping fields from
the same section of the individual rat renal cortex were photo-
graphed under 200x magnification, and the number of ED-i
positive cells was calculated and averaged (cells/200x field). The
average score of samples from three separate animals was then
averaged.
A standard point counting method was used to quantitate the
volume of the renal cortex occupied by interstitium, tubules,
glomeruli and fluid space (tubular lumen and Bowman's space)
[171. The relative volume (Vv) of the renal cortical interstitium
was determined on sections using the Azan-Mallory method to
stain collagen fibers in tubular basement membrane (TBM),
glomeruli, and interstitial space, as described previously [6, 13,
14]. One point count study evaluated interstitium only and was
based on 1170 points for each kidney. Another point count study
was performed to evaluate the interstitium, tubule, glomerular
and fluid space volume. For this study, fields containing only one
glomerulus were counted and 100 points in six different fields
within each kidney were evaluated.
The matrix score for collagen IV and a-smooth muscle expres-
sion in the renal cortical interstitium was determined as described
previously [6, 14]. Twenty random, non-overlapping fields of
sections stained for collagen IV were assigned a score of zero to
three (a score of zero was equivalent to the results in a normal
kidney). Progressively higher scores were assigned depending on
the degree and amount of interstitium that reacted with the
antibodies specific for collagen IV or a-smooth muscle actin. The
scores of the twenty fields of each kidney were averaged. The
average scores of samples from three separate animals were then
averaged.
Characterization and quantitation of TGF-f31, TJMP-1, and
collagen a(IV) mRNA by reverse transcription-polymerase chain
reaction (RT-PCR)
Oligo dT primed first strand eDNA was synthesized with a
eDNA cycle kit from Promega (Madison, WI, USA) using 2 jig of
total RNA for TGF-f31 and TIMP-1, and 4 jig for collagen IV.
The mixture of total RNA (2 jig or 4 j.tg/10 jil RNAse-free water)
and oligo dT (1 j.tl) was incubated at 65°C for 10 minutes to
denature the secondary structure and chilled on ice immediately.
The resulting mixture was incubated at 42°C for one hour after
adding 5 units of avian myeloblastic virus transcriptase, heated to
94°C for five minutes and chilled on ice. A second round of
reverse transcription was performed after adding 5 units of
enzyme.
Polymerase chain reaction (PCR) was performed using 3 jil of
each eDNA incubation. Amplification was done in a total volume
of 50 jil containing PCR buffer (50 mM KCI, 10 mM Tris-HCI), 1.5
mM MgCl2, 200 jiM of each dNTP, 50 pmol of oligonucleotide
primers for TGF-[31, 25 pmol for TIMP-J, or 100 pmol for
collagen IV, and 1.25 units of Taq DNA polymerase (Promega).
In order to quantitate PCR products and to confirm the integrity
of the RNAs we coamplified a housekeeping gene, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) in companion tubes.
We used a small amount (1 pi) of eDNA from the cortex with 25
pmol of primers to ampli' the GAPDH message. The TGF-/31
primers were designed from the sequence of the rat gene:
5'-AATACGTCAGACATI'CGGGAAGCA (sense) from exon 2
and 3' -GTCAATGTACAGCTGCCGTACACA (antisense) from
exon 6 to yield a 498 bp product [18]. The TIMP-1 primers were
designed from the sequence of the murine gene: 5'-GACCTG-
GTCATAAGGGCTAAA (sense) and S '-GCCCGTGATGAGA-
AACTCTT'CACT (antisense) to yield a 216 bp product [19]. The
collagen al(IV) primers were designed from the sequence of the
murine gene: 5' -GTGCGGTTTGTGAAGCACCG (sense) and
3'-GTFCTTCTCATGCACACTT (antisense) to yield a 363 bp
product [20]. The GAPDH primers were designed from the
sequence of the rat gene: 5'-AATGCATCCTGCACCACCAA
(sense) and 3 '-GTAGCCATATTCA'flTGTCATA (antisense) to
yield a 515 bp product [21]. PCR was performed with a Perkin
Elmer Cetus DNA Thermal Cycler using the following program:
zr
: ¶ -' If1 Fk 1..
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Fig. 1. Effect of delayed enalapril treatment on
the histology of the kidney cortex of rats with
ureteral obstruction. Shown are representative
sections of kidney from untreated rats three
days after obstruction (A) and eight days after
obstruction (B) and from rats treated with
enalapril from day 4 to day 8 after the onset of
obstruction (C). Also shown are representative
sections of kidney from untreated rats five days
after obstruction (D) and 10 days after
obstruction (E) and from rats treated with
enalapril from day 6 to day 10 after the onset
of obstruction (F).
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Fig. 1. Continued.
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94°C for one minute (denaturing), 60°C for one minute (anneal-
ing) (56°C with TIMP-1 primers and 54°C with collagen IV
primers), and 72°C for two minutes (extension). Amplifications
were carried out at 26 cycles with TGF-/31 primers, 35 cycles with
TIM P-i primers, 40 cycles with collagen IV primers, and 28 cycles
with GAPDH primers.
PCR products were quantitatively analyzed as described previ-
ously [6, 13, 14]. After amplification, 15 1.d of each PCR reaction
mix was electrophoresed through a 1.2% agarose gel with
ethidium bromide (0.5 tg/ml). The gel was photographed with
Polaroid Type 665 positive/negative film (Polaroid Corporation,
Cambridge, MA, USA) over UV light at the same exposure and
development time for all gels photographed. The bands on the
negative film were scanned by densitometry (Sepra Scan 20001
software, Integrated Separation System, Natwick, MA, USA) for
quantitation. The PCR products of TGF-pl and GAPDH,
TIMP-1 and GAPDH, or collagen IV and GAPDH (those
amplified from the same cDNA) were electrophoresed in the
same gel and ratios for TGF-131/GAPDH, TIMP-1/GAPDH, or
collagen IV/GAPDH were determined to eliminate gel-to-gel or
film-to-film variance.
Statistical analysis
Data, shown as mean SD, were analyzed by unpaired I-test on
the Macintosh Stat View program. Comparison between values
for the contralateral kidney and obstructed kidney were per-
formed using a paired t-test. ANOVA was employed to determine
the significance of the relative volume of the renal interstitium
(Vv), ED-I positive cell infiltration, a-smooth muscle actin matrix
score, and collagen IV matrix score.
Results
Morphometric analysis
Microscopic sections obtained from the experimental kidney of
animals three days after the onset of obstruction revealed a
slightly expanded interstitium and a cellular infiltrate (Fig. 1A).
The experimental kidney of rats with ureteral obstruction of eight
days duration had a greatly expanded interstitium, which was
occupied by many cellular elements (Fig. 1B). The obstructed
kidney of rats treated from day 4 to day 8 with enalapril had a
modest increase of interstitial cellularity (Fig. IC) above that seen
on day 3 in those animals (Fig. 1A), but not to the extent seen on
day 8 (Fig. 1B) in animals not receiving enalapril.
Examination of sections obtained from the obstructed kidney
after five days or 10 days of ureteral obstruction revealed a greatly
expanded interstitium with a considerable amount of cellularity
(Fig. 1 D and E, respectively). In the obstructed kidney of rats
treated from day 6 to 10 with enalapril there was a decrease in
cellularity in many areas (Fig. lF). Some areas of the obstructed
kidney treated from day 6 to 10 did, however, contain a hypercel-
lular intcrstitium (Fig. iF).
The relative volume of the cortical interstitium was expressed as
the volume fraction (Vv) (Fig. 2A). The Vv of the obstructed
kidney was significantly increased (P < 0.01) at three and eight
days of obstruction. After three days of obstruction, Vv was 17.2
2% and 8 1% in the obstructed kidney and contralateral
kidney, respectively; at eight days of obstruction, Vv was 41.8
5.1% and 9 1.8% in the obstructed kidney and contralateral
kidney, respectively. Administration of enalapril from days 4
through 8 after the onset of obstruction resulted in a significantly
lesser increase in the interstitial volume, to 25.8 3.4%, than was
seen in the obstructed kidney of untreated rats (P < 0.01). No
significant difference was detected in the Vv of the contralateral
kidney between days 3 and 8 in rats with UUO, and there were no
differences in the contralateral kidney between untreated and
enalapril treated animals at day 8. The Vv of the contralateral
kidney in each group was not significantly different from that
measured in the kidneys of sham-operated rats (9.7 1.2, N = 3;
Fig. 2A).
The Vv of the obstructed kidney at five days (38.7 1.5) and 10
days (43.3 4.6) of UUO was not significantly different from that
of the obstructed kidney of rats with UUO of eight days duration
(compare Fig. 2 A and B). The standard deviations after 8 or 10
days of obstruction for Vv measurements were considerably
increased compared to that of day 5 measurements due to the
variability in the widening of the interstitium beyond day 5. Treat-
ment with enalapril from day 6 to day 10, however, resulted in a Vv
of 32.3 4.9% in the obstructed kidney. This is significantly less than
the Vv of the obstructed kidney of untreated rats at either day 5
(P < 0.05) or at day 10 (P < 0.01). The Vv of the contralateral
kidney of rats with UUO was not significantly different from that
of the kidneys of 8-day sham-operated rats (Fig. 2A).
In a smaller point count study using three different animals
under each condition, we evaluated the amount of cortical volume
occupied by interstitium, tubules, glomeruli, and the fluid space
(Table 1). This study indicates that the volume occupied by
glomeruli did not significantly change over the 10-day duration of
UUO or with enalapril treatment. With the exception of the levels
measured on day 3 of UUO, the fluid volume (lumen plus
Bowman's space) was not significantly changed (Table 1). As the
volume of cortex occupied by interstitium significantly increased
there was a reciprocol significant decrease in the volume occupied
by tubules (Table 1).
Monocyte/macrophage infiltration of the kidney during UUO
Figure 3A depicts the infiltration of the renal cortex of the
obstructed kidney by ED-i positive monocytes/macrophages after
three and eight days of obstruction. At day 8, the obstructed
kidney showed a significant increase in the number of ED-i
positive cells compared to the obstructed kidney at day 3 (P <
0.001). Figure 3A also shows the number of ED-i positive
monocytes/macrophages in the obstructed kidney of rats treated
with enalapril from day 4 through day 8. The delayed administra-
tion of enalapril resulted in significantly less ED-I positive cell
infiltration: an average of 37.3 7.5 cells per field compared to
114.3 21.5 cells per field in the untreated kidney (P < 0.01; Fig.
3A). There were no significant changes in the number of ED-i
positive cells in the contralateral kidney of all three groups of rats
with unilateral ureteral obstruction from that seen in the kidneys
of sham-operated rats.
Figure 3B shows that the number of ED-i positive monocytes/
macrophages in the obstructed kidney at day 10 of UUO (83.9
5.1 cells per field) is significantly increased over the number found
at day 5 of UUO (67.8 3.3 cells per field). Delaying the
initiation of enalapril treatment until day 6 of obstruction resulted
in significantly less ED-I positive cell infiltration (62.6 9.2 cells
per field) than was seen in untreated animals on day 10. Although
slightly reduced, the monocyte/macrophage infiltrate measured
on day 10 of delayed treatment was not significantly different from
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Table 1. Fractional volumes of interstitium (Vv1), tubules (VvTUh),
glomeruli (Vv01) and fluid space (VvFS) of kidney cortex
Condition Vv1,, Vv.f,h VV0im VvFS
Fig. 2. Effect of delayed enalapril treatment on the interstitial volume (Vv) of
the kidney cortex of rats with ureteral obstruction. (A) The Vv of the
contralateral (C) and ureteral obstructed (0) kidneys represents the mean
SD of 3 untreated animals three days after obstruction, 4 untreated
animals eight days after obstruction, 4 animals treated with enalapril on
day 4 through day 8 after obstruction, and 3 sham-operated animals eight
days after manipulation but not obstruction of the ureter. (B) The Vv of
the contralateral (C) and the ureteral obstructed (0) kidneys represents
the mean SD of 3 untreated animals five days after obstruction, 3
untreated animals 10 days after obstruction, 3 animals treated with
enalapril on day 6 through day 10 after obstruction, and 3 normal (N)
animals, *p < 0.01, sham, (N) or (C) versus (0) at each time point and
treatment status. + +P < 0.01, untreated obstructed kidney versus ob-
structed kidney treated with enalapril. The Vv of obstructed kidney from
the animals treated from days 6 to 10 with the ACE inhibitor is
significantly less than that of obstructed kidney from untreated animals at
day 5 after obstruction was initiated (P < 0.05).
that seen on day 5, prior to initiating treatment with the ACE
inhibitor (Fig. 3B). As was seen with the Vv, the SD of the infiltrate
measurements was increased due to the somewhat focal nature of
the infiltrate measured in different microscopic fields of the same
histologic section.
Immunohistochemical studies on collagen IV and a-smooth
muscle actin
We have shown previously a progressive increase in collagen IV
protein in the interstitium of the obstructed kidney [6, 141. The
up-regulation of collagen IV protein in the renal cortex and the
impact of delayed treatment with the ACE inhibitor on this
process was assessed using the matrix score technique [6, 14].
Table 2 illustrates that between day 3 and 8 of UUO there was a
significant increase in the collagen IV content of the interstitium.
Treating animals with enalapril on day 4 through day 8 of UUO
8.7 1.2 56.0 5.3 6.3 1.5 29.0 3.0
8.1 1.0 59.3 3.1 6.7 1.2 26.0 1.7
38.0 3.0 32.0 3.5 6.7 1.5 23.3 2.6
9.7 [.2 59.3 4.2 6.7 1.5 24.3 4.7
untreated
dp < 0.05, 10 day obstructed treated compared to 10 day obstructed
untreated
P < 0.04, 3 day obstructed compared to all other conditions
effectively limited the increase in interstitial protein deposition to
a value not significantly different from that seen after three days of
obstruction. The matrix score of the sham-operated kidneys was
zero.
The matrix score for collagen IV in the obstructed kidney of
rats after 10 days of continuous UUO without treatment was
significantly different from that found at day 5 of UUO (Table 2).
There was a slight increase from the score seen at day 8 of UUO
(Table 2). Enalapril treatment initiated at day 6 of UUO signifi-
cantly retarded the increase in collagen IV within the matrix and
reduced the matrix collagen IV content to below that seen at day
5 of UUO.
We have also previously shown that a-smooth muscle actin is
expressed by interstitial cells of the obstructed kidney [14]. As
shown in Table 3, there is a marked increase in the a-smooth
muscle actin matrix score between day 3 and dayS of UUO. There
is no marked change in the matrix score for a-smooth muscle actin
between days 5, 8, and 10 of continuous untreated UUO. Enala-
pril treatment initiated on day 4 of UUO significantly blunted the
increase in matrix score at day 8. There was a significant reversal
(decrease) in the a-smooth muscle actin matrix score when
enalapril treatment was initiated on day 6 and the animals
sacrificed on day 10 of UUO (Table 3).
Time course expression of TGF-pl mRNA, TIMP-1 mRNA and
collagen IV mRNA during UUO
As reported previously [6, 13, 14], the obstructed kidney of
untreated rats with UUO showed a prominent increase in
9.7 1.2
7.7 1.2
16.3 isa
9.0 1.0
58.0 5.6
59.7 3.8
42.0 iT'
58.0 4.6
6.7 0.6
7.0 1.0
6.7 1.2
6.3 1.2
25.7 5.7
26.7 4.5
35.0 2.0c
26.7 2.9
40.0 4.1k' 30.3 4.0" 6.3 1.2 23.3 1.5
9.3 1.2 58.7 3.2 6.7 1.5 25.0 5.8
20.7 3.ic 46.7 1.2c 7.0 1.0 26.0 2.1
Sham
Day 3, Contralateral
Day 3, Obstructed
Day 8, Contralateral
untreated
Day 8, Obstructed
untreated
Day 8, Contralateral
treated
Day 8, Obstructed
treated
Normal
Day 5, Contralateral
Day 5, Obstructed
Day 10, Contralateral
untreated
Day 10, Obstructed
untreated
Day 10, Contralateral
treated
Day 10, Obstructed
treated
41.7 5.0 30.7 4.3 6.0 1.0 22.0 3.0
9.0 2.0 59.7 3.1 6.0 2.0 25.0 1.0
31.0 4,3C 39,7 3,6d 6.3 0.6 23.0 1.0
Values are the mean SD of 3 different animals and represent the
percent volume of rat kidney cortex occupied by the structure.
a P < 0.01, obstructed compared to sham, normal, or same day
contralateral
"P < 0.02, 8 day obstructed compared to 3 day obstructed
"P < 0.01, 10 day obstructed treated compared to 10 day obstructed
A
*
140
120
100
80
60
40
20
0
CO
Day 8Day 3 Day 8
ACE inhibitor
treated
100
F
90
80
70
60
50
40
20
30
10
0
tt
*
Day 8
Sham
* tt
*
CO CO
Day 10 Day 10
ACE inhibitor
treated
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Table 2. Collagen IV matrix score of the obstructed kidney
Fig. 3. Effect of delayed enalapril treatment on the ED-i monocyte/macro-
phage infiltration of the kidney cortex of ureteral obstructed rats. (A) The
number of ED-i positive cells in the sham-operated, contralateral (C) and
ureteral obstructed (0) kidneys is shown as the mean SD of determi-
nations in 3 separate animals at each time point and treatment status. (B)
The number of ED-I positive cells in the contralateral (C) and the ureteral
obstructed (0) kidneys represents the mean so of 3 untreated animals
five days after obstruction, 3 untreated animals 10 days after obstruction,
3 animals treated with enalapril on day 6 through day 10 after obstruction,
and 3 normal animals. *p < 0.01, infiltration in (C), normal (N) or sham
versus (0) at each time point and treatment status. + +P < 0.01,
infiltration in untreated obstructed kidney versus obstructed kidney
treated with enalapril.
TGF-/31 mRNA levels as compared to the contralateral kidney of
the same rats or kidneys of sham operated or normal animals at
each time point (Fig. 4). Treatment with enalapril on day 4
through day 8 or from day 6 to day 10 after UUO significantly
limited the increased expression of TGF-/31 mRNA both in the
obstructed kidney and in the contralateral kidney.
The time course of changes in TIMP-1 mRNA in the rats with
UUO resembled that of TGF-pl (Fig. 5). A significant difference
between the obstructed kidney and the normal or sham-operated
kidneys was detected at each time point and the obstructed kidney
at day 10 showed a 3.8-fold increase over "normal" values. The
contralateral kidney showed a significant increase as compared to
"normal" kidneys at each time point. Enalapril treatment on day
4 through day 8 or day 6 through day 10 significantly blunted the
increased expression of TIMP-i mRNA both in the obstructed
kidney and in the contralateral kidney.
Like TGF-/31 mRNA and TIMP-1 mRNA, collagen IV mRNA
levels in the obstructed kidney of untreated rats with UUO
increased steadily with time (Fig. 6). Administration of enalapril
from day 4 through day 8 or from day 6 through day 10
Day 3, Untreated 0 58 8 42 8 0 1.42 0.08
Day 8, Untreated
Day 8, Treated
0
0
0
37 8
42 3
48 3 58 315 5 2.58 0.03"1.62 010h
from day 4 to day 8
Day 5, Untreated 0 8 3 52 7 40 5 2.32 0.06
Day 10, Untreated
Day It), Treated
0
0
0
19 4
23 3
50 10
77 3
31 12
2.77 0.03c
2.07 0.13"
from day 6 to day 10
Condition
Score
Average
score0 1 2 3
Day 3, Untreated 50 5 50 5 0 0 0.50 0.05
Day 8, Untreated
Day 8, Treated
0
28 6 060 5 47 312 3 53 30 2.53 0.03'0.83 008h
from day 4 to day 8
Day 5, Untreated 0 0 42 4 58 4 2.58 0.04
Day 10, Untreated
Day 10, Treated
0
0
017 2 40 450 6 60 434 6 2.60 0.042.17 0.07"
from day 6 to day 10
significantly blunted the increased expression of collagen IV
mRNA in the obstructed kidney. There was a significant (P <
0.01) decrease in the amount of collagen IV mRNA in the
contralateral kidney of animals treated with the ACE inhibitor
from days 4 to 8. No such effect was seen in the contralateral
kidney of animals treated from days 6 to 10.
Discussion
Numerous experimental models of renal disease have been
studied. In some of these models, glomerular injury precedes
tubulointerstitial damage [22, 231, while in others tubulointersti-
tial changes occur first [241. Unilateral ureteral obstruction
(UUO) is a well established experimental model [5—10, 13, 14] in
which progressive fibrosis of the tubulointerstitium is prominent.
This ultimately leads to "destruction" of both glomeruli and
tubules of the experimental kidney [5, 11].
The renin-angiotensin system (RAS) is up-regulated in rats
with UUO within 24 hours of obstruction [25, 26]. It is highly
likely that the development and progression of tubulointerstitial
fibrosis in rats with UUO is related to increased levels of
angiotensin H in the experimental kidney [6, 14]. In previous
studies, we found that inhibition of Ang II formation prior to or
concomitant with the onset of ureteral obstruction ameliorated
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Fig. 4. Ratio of TGF-j31 to GAPDH tnRNA in the kidney cortex of ureteral
obstructed rats. Abbreviations are as in Figure 4. (A) The ratio rcpresents
the mean SD of determinations in 3 animals three days after obstruction,
4 (untreated) animals eight days after obstruction, 4 animals treated with
enalapril on day 4 through day 8 after obstruction, and 3 sham-operated
animals eight days after manipulation but not obstruction of the ureter.
(B) The ratio represents the mean SD of determinations in 5 animals five
days after obstruction, S animals (untreated) 10 days after obstruction, 5
animals treated with enalapril on day 6 through day 10 after obstruction
and 3 normal animals. *J) < 0.01, ratio in ureteral obstructed versus
normal or sham-operated kidneys. * *p < 0.02, ratio in contralateral
versus normal or sham-operated kidneys. +P < 0.01, ratio in untreated
versus treated contralateral kidneys. + +P < 0.001, ratio in untreated versus
treated obstructed kidneys.
the leukocyte influx, the hemodynamic events, and the severity of
tubulointerstitial fibrosis in this model. In the present study we
inhibited angiotensin II formation after UUO was established and
a significant degree of tubulointerstitial fibrosis had occurred,
Delayed administration of an ACE inhibitor slowed if not halted
the progression of the tubulointerstitial fibrosis in the experimen-
tal kidney of rats with unilateral ureteral obstruction.
At present we do not know how extensively fibrosis of the
interstitium can progress before ACE treatment would become
ineffective. Indeed, as shown in Figure 1 and from the wider
standard deviations shown in Figures 2 and 3, there is consider-
able variation within the span of one 200x microscope field. The
overall picture is that treatment with enalapril does effectively
decrease the cellularity within the interstitium during both treat-
ment regimes. A corollary to that generalization, however, is that
delaying treatment until day 6 is not quite as effective as beginning
it on day 4. Interestingly, previous studies in an experimental
model of glomerulosclerosis reported that glomeruli in an ad-
Fig. S. Ratio of TJMP-1 to GAPDH mRt'JA in the kidney cortex of ureteral
obstructed rats. See Figure 4 for details. p < 0.01, ratio in obstructed ver-
sus normal or sham-operated kidneys. < 0,01, ratio in contralate-
ral versus normal or sham-operated kidneys. +P C 0.001, ratio in untreated
versus treated contralateral kidneys. + +P C 0.001, ratio in untreated versus
treated obstructed kidneys.
vanced stage of sclerosis were refractory to treatment with an
ACE inhibitor [27, 28], unlike glomeruli with early histologic signs
of sclerosis.
In the present study we found that the increase in the fractional
volume of the kidney cortex occupied by interstitium was balanced
by a decrease in the fractional volume occupied by the tubules.
This reciprocal relationship of interstitium and tubules was also
seen in the development of cyclosporine nephropathy and treat-
ment with ACE inhibitor [291. During uretcral obstruction the
size of the kidney increases in rats. Therefore, as the interstitium
expands with proliferating fibroblasts and matrix protein deposi-
tion the tubules are pushed apart and displaced from each other
and from peritubular capillaries. These observations in the rat are
consistent with ultrastructural changes observed in human chronic
hydronephrosis [17].
Although we gave relatively high doses of enalapril (200
mg/liter in the drinking water, 30 mg/kg/day equivalent), which
undoubtedly decreased the blood pressure of the animals, results
of a previous study indicate that the beneficial effect of ACE
inhibitors in tubulointerstitial fibrosis is by and large independent
of their effect on blood pressure [141. A previous study concerning
glomeruloselerosis indicated that ACE inhibition had a beneficial
effect beyond that needed to reduce blood pressure [27]. It is also
worth noting that in this study the enalapril treated animals drank
the same amount of water and appeared to consume the same
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Fig. 6. Ratio of collagen IV to GAPDH mRNA in the kidney cortex of
ureteral obstructed rats. See Figure 4 for details. *p < 0.01, ratio in
obstructed versus normal or sham-operated kidneys. < 0.02, ratio
in contralateral versus normal or sham-operated kidneys. +P < 0.01, ratio in
untreated versus treated contralateral kidneys. + +P < 0.005, ratio
in untreated versus treated obstructed kidneys.
amount of food as the untreated animals. Therefore the nutri-
tional status of the treated animals was no different from that of
the untreated animals.
The eventual increase in collagen IV protein deposition is due
to the increase in the mRNA for the protein and a presumed
increase in TIMP-1. Diamond et al [30] and Sharma et al [311 have
suggested that infiltrating macrophages are the source of TGF-f31,
and that macrophages and TGF-f31 regulate TIMP-1 gene expres-
sion and the subsequent accumulation of collagen IV [26, 31]. In
the present study TGF-/31 mRNA and TIMP-1 mRNA changed in
parallel. Whether macrophages are the source of TGF-/31 in the
obstructed kidney of rats with UUO remains to be determined. Of
note in our study is the fact that the interstitial volume, TGF-p1
mRNA, TIMP-1 mRNA and a-smooth muscle actin expression
were significantly less at day 10 of obstruction in the rats treated
with enalapril as compared to the levels found at day 5 of ureteral
obstruction in untreated animals. This suggests that a reversal of
some of the elements responsible for fibrosis had occurred. A
myofibroblast phenotype develops in the interstitium [8, 14] and
may be a sensitive indicator of the driving forces for fibrosis of the
interstitium.
The changes in mRNA levels in the contralateral kidney of rats
with UUO (see Results) are noteworthy. Sharma et al examined
cortical interstitial volume fraction and collagen IV mRNA in
rabbits with UUO for 16 days and reported no significant differ-
ence in these two factors between the contralateral kidney and the
kidneys of sham-operated animals [10]. Similar findings occurred
when measuring TIMP-1 mRNA [311. Diamond and coworkers
studied TGF-/31 mRNA levels in the four days following the
initiation of UUO in rats; kidney sections were stained immuno-
histologically using anti TGF-j31 antibody. There was neither a
significant increase in TGF-f31 mRNA nor TGF-131 positive
staining in the contralateral kidney [301. It is possible that
Northern blot analysis, used in that study, is not as sensitive as the
RT-PCR we describe in the present report. Although histologi-
cally we could not detect significant increases of Vv, collagen IV,
matrix score, and ED-i positive monocytes/macrophages in the
contralateral kidney even at day 10 of obstruction, the contralat-
eral kidney demonstrated a 2.8-fold increment in TGF-/31 mRNA,
a 2.4-fold increment in TIMP-1 mRNA, and a 1.7-fold increase in
collagen IV mRNA, respectively, whereas there were no such
increases in kidneys of sham-operated rats. In a biochemical study
of rats with UUO hydroxyproline incorporation into the contralat-
eral kidney was increased about sixfold over that of the normal
kidney at 15 days of UUO [32]. In the same study collagenolytic
activity was decreased by 20%. This correlates with our studies,
suggesting that molecular mechanisms in the contralateral kidney
are posed for increasing collagen synthesis.
Our experimental data suggest that ACE inhibitors may be a
possible pharmacotherapeutic intervention in patients with ob-
structive nephropathy. In the present study we specifically docu-
mented changes in the levels of TIMP-1 mRNA in kidney tissue.
TIMP-1 is by definition an inhibitor of metalloproteinases, and as
such would normally degrade excess matrix protein [15]. For a
therapeutic process to effectively resolve established fibrotic pro-
cesses in the kidney, an increase in metalloproteinase activity is as
necessary as a decrease in the synthesis of matrix proteins.
Enalapril effectively decreased TIMP-1 mRNA levels or at least
prevented them from increasing. This in turn would result in
increased collagenolytic activity and lead to a decrease in the total
amount of collagen present in the interstitium. The collagenolytic
activity of the obstructed kidney is decreased by 90% at 15 days of
UUO [32].
In summary, this study reports the time course of tubulointer-
stitial fibrosis in the setting of UUO. The Vv, collagen IV,
a-smooth muscle actin, and monocyte/macrophage content of the
interstitium in the obstructed kidney of rats with UUO increased
with time. Administration of enalapril until three or five days after
UUO was initiated largely prevented the progression of tubulo-
interstitial fibrosis in rats with UUO beyond that already present
when enalapril was begun. This observation has therapeutic
implications as to the possible use of ACE inhibitors in patients
with obstructive nephropathy.
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